other material
confidence high
sentiment positive
materiality 0.80
Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed
Nkarta, Inc.
- 7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.
- No dose-limiting toxicity, ICANS, GvHD, or >Gr3 CRS; safety profile supports outpatient administration.
- Durable responses >6 months seen; 5 CRs after one cycle, 3 partial responses deepened to CR with additional cycles.
- Dose expansion open: monotherapy in LBCL (CAR T naive/experienced) and combination with rituximab.
- Conference call held Dec 5, 2022; NKX019 is an off-the-shelf allogeneic CAR-NK therapy targeting CD19.